Abciximab

Administration

• Type: Glycoprotein IIB/IIIA inhibitor
• Dosage Forms: Injection
• Routes of Administration: IV
• Common Trade Names: Reopro

Adult Dosing

PCI Adjunct

• 0.125 mcg/kg/min IV x 12h
  • Part of multidrug regiment with heparin and aspirin

Unstable angina, refractory

• 10 mcg/min IV x 18-24h
  • Part of multidrug regiment with heparin and aspirin

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

• Benefits outweigh risks during pregnancy
• Inadequate human data available to assess risk
• Risk of maternal hemorrhage during delivery

Lactation risk

• May use while breast feeding

Renal Dosing

• Adult: Not defined
• Pediatric: Unavailable

Hepatic Dosing

• Adult: Not defined
• Pediatric: Unavailable

Contraindications

• Allergy to class/drug
• Hypersensitivity to murine proteins
• Active internal bleeding
• GI/GU bleeding w/in 6 weeks
• Stroke w/in 2 years
• Coagulation disorder
• Plt < 100,000
• INR > 1.2
• Recent surgery or trauma
• HTN, uncontrolled
• Intracranial neoplasm, AVM, or aneurysm
• Vasculitis hx
• Dextran use in coronary procedure

Adverse Reactions

Serious

• Thrombocytopenia
• Bleeding
• AV Block, complete
• Anaphylaxis

Common

• Bleeding, hypotension
• Back pain, chest pain, abdominal pain
• Peripheral edema
• Nausea, vomiting
• Headache, dizziness
• Bradycardia

Pharmacology

• Half-life: <10 min initially then 30 min second phase
• Metabolism: Other
• Excretion: Urine

Mechanism of Action

Binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation